Ocular Therapeutix (OCUL) Free Cash Flow (2013 - 2026)

Ocular Therapeutix's Free Cash Flow history runs 14 years deep, the most recent figure standing at -$67.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 44.45% year-over-year to -$67.3 million; the TTM figure through Mar 2026 stood at -$226.8 million (down 53.99% YoY), while the FY2025 annual figure was -$206.1 million, down 52.86% from the prior year.
• Free Cash Flow was -$67.3 million for Q1 2026 at Ocular Therapeutix, down from -$46.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$8.0 million in Q3 2023 to a low of -$67.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$31.9 million across 5 years, with a median of -$25.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow surged 45.92% in 2022, then sank 345.98% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$20.2 million in 2022, then increased by 16.61% to -$16.8 million in 2023, then slumped by 134.38% to -$39.5 million in 2024, then fell by 17.17% to -$46.3 million in 2025, then tumbled by 45.55% to -$67.3 million in 2026.
• The last three Free Cash Flow figures came in at -$67.3 million (Q1 2026), -$46.3 million (Q4 2025), and -$56.7 million (Q3 2025), per Business Quant data.